Conduit Pharmaceuticals Inc.

CDT

US20678X1063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
3.04 ^USD	+1.33%		+7.04%	-33.19%

14/05	Conduit Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
19/03	Conduit Pharmaceuticals Inc. Appoints Joanne Holland as Chief Scientific Officer	CI

Conduit Pharmaceuticals Inc. announced that it has received $20 million in funding from Nirland Limited

September 22, 2023

On September 22, 2023, Conduit Pharmaceuticals Inc. closed the transaction.

Latest news about Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Conduit Pharmaceuticals Inc. Appoints Joanne Holland as Chief Scientific Officer	19/03	CI
Conduit Pharmaceuticals Inc. Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub	11/03	CI
Conduit Pharmaceuticals Inc.(NasdaqGM:CDT) added to S&P TMI Index	18/12	CI
Top Premarket Decliners	30/11	MT
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	30/23/30	MT
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday	30/23/30	MT
Top Premarket Gainers	30/23/30	MT
Top Premarket Gainers	25/23/25	MT
Conduit Pharmaceuticals, ClinConnect Enter Drug Development Collaboration	11/23/11	MT
ClinConnect Partners with Conduit Pharmaceuticals on Cocrystal Development Program for AZD1656	11/23/11	CI
Top Premarket Gainers	04/23/04	MT
Top Premarket Decliners	26/23/26	MT
Conduit Pharmaceuticals Inc.(NasdaqGM:CDT) added to NASDAQ Composite Index	26/23/26	CI
Conduit Pharmaceuticals Inc. announced that it has received $20 million in funding from Nirland Limited	22/23/22	CI
Conduit Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	11/23/11	CI
Conduit Pharmaceuticals Inc. announced that it expects to receive $27 million in funding from Nirland Limited	08/22/08	CI

Chart Conduit Pharmaceuticals Inc.

Duration

Period

More charts

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Companyâs licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimotoâs Thyroiditis. The Companyâs asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimotoâs Thyroiditis (HT and Gravesâ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimotoâs Thyroiditis and Gravesâ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).

Sector

Biotechnology & Medical Research

Calendar

14/11/2024 - Jefferies London Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CONDUIT PHARMACEUTICALS INC.	-33.19%	224M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B